Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer’s disease

Bibliography

• CUMMINGS JL, KAUFER D: Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revis-ited. Neurology (1996) 47:876–883.
   PubMed Web of Science ®Google Scholar
• WHITEHOUSE PJ, PRICE DL, CLARK AW et al.: Alz-heimer's disease: evidence for selective loss of cho-linergic neurons in the nucleus basalis. Ann. Neurol (1981) 10:122–126.
   PubMed Web of Science ®Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMON PR et al.: A 30-week randomized controlled trial of high-dose tacrine in pa-tients with Alzheimer's disease. JAMA (1994) 271: 985–991.
   PubMed Web of Science ®Google Scholar
• ROSEN WG, MOHS RC, DAVIS KL: A new rating scale forAlzheimer's disease. Am. J. Psychiat. (1984) 141: 1356–1364.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FARLOW MR, DOODY RS, DONEPEZIL STUDY GROUP: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alz-heimer's disease. Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• HINZ VC, GREWIG S, SCHMIDT BH: Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem. Res. (1996) 21:331–337.
   PubMed Web of Science ®Google Scholar
• TAYLOR P: Anticholinesterase agents. In: The Pharma-cological Basis of Therapeutics. Goodman Gilman A, Rail TW, Nies AS et al. (Eds.), Pergamon Press, Elmsford, UK (1990131–149.
   Google Scholar
• ••An overview of the pharmacology of anticholinesterasedrugs, including organophosphates, with information on managing toxicity.
   Google Scholar
• PACHECO G, PALACIOS-ESQUIVEL R, MOSS DE: Cholin-esterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholines-terase. J. Pharmacol. Exp. Ther. (1995) 274:767–770.
   PubMed Web of Science ®Google Scholar
• GIACOBINI E: The second generation of cholinesterase inhibitors: pharmacological aspects. In: Cholinergic Ba-sis for Alzheimer Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1991):247–262.
   Google Scholar
• OGANE N, GIACOBINI E, MESSAMORE E: Preferential in-hibition of acetylcholinesterase molecular forms in rat brain. Neurochem. Res. (1992) 17:489–495.
   PubMed Web of Science ®Google Scholar
• HALLEK M, GIACOBINI E: A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharma-cology (1987) 26:521–530.
   PubMed Web of Science ®Google Scholar
• SCALI C, GIOVANNINI MG, BARTOLINI L et al: Effect ofmetrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur. J. Pharmacol. (1997) 325:173–180.
   PubMed Web of Science ®Google Scholar
• SCALI C, GIOVANNINI MG, BARTOLINI L et al: Effect ofsubchronic administration of metrifonate on extracel-lular acetylcholine levels in aged F344 rats. Biol. Psy-chiat. Abstr. (1997) 42:121S.
   Google Scholar
• MORI F, CUADRA G, GIACOBINI E: Metrifonate effectson acetylcholine and biogenic amines in rat cortex. Neurochem. Res. (1995) 20:1081–1088.
   PubMed Web of Science ®Google Scholar
• BASSANT MH, POINTDESSOUS F, LAMOUR Y: Sub-chronic treatment with metrifonate increases brain metabolism in young and aged rats. Biol. Psychiat. Abstr. (1997) 42:22S.
   Google Scholar
• SCHMIDT BH, BJORKLAND M, RIEKKINEN M et al.: A cho-linesterase inhibitor, metrifonate, desynchronizes neocortical EEG activity in rats. Soc. NeuroscL Abstr. (1996) 22:2121.
   Google Scholar
• ITOH A, NITTA A, KATONO Y et al: Effects of metrifo-nate on memory impairment and cholinergic dysfunc-tion in rats. Eur.J. Pharmacol. (1997) 322:11–19.
   PubMed Web of Science ®Google Scholar
• RIEKKINEN P, SCHMIDT BH, STEFANSKI R et al.: Metrifo-nate improves spatial navigation and avoidance be-havior in scopolamine-induced, medial septum-lesioned and aged rats. Eur. J. Pharmacol. (1996) 309:121–130.
   PubMed Web of Science ®Google Scholar
• VAN DER STAAY FJ, HINZ VC, SCHMIDT BH: Effects ofmetrifonate on escape and avoidance learning in young and aged rats. Behav. Pharmacol. (1996) 7:56–64.
   PubMed Web of Science ®Google Scholar
• BLOKLAND A, HINZ V, SCHMIDT BH: Effects of metrifo-nate and tacrine in the spatial Morris task and modi-fied Irwin test: evaluation of the efficacy/safety profile in rats. Drug Dev. Res. (1995) 36:166–179.
   Web of Science ®Google Scholar
• SCHMIDT BH, HINZ VC, VAN DER STAAY FJ: Cognitionenhancement by metrifonate: evidence from animal studies. In: Alzheimer's Disease: Biology, Diagnosis, and Therapeutics. Iqbal K, Winblad B, Nishimura T et al. (Eds.), John Wiley & Sons, Ltd. (1997):784–786.
   Google Scholar
• •A survey of the studies of metrifonate's effects on memory in animals.
   Google Scholar
• UNNI LK, WOMACK C, HANNANT ME et al: Pharmacoki- netics and pharmacodynamics of metrifonate in hu-mans. Meth. Find. Exp. Clin. Pharmacol (1994) 16:285–289.
   PubMed Web of Science ®Google Scholar
• NORDGREN I, BENGTSSON E, HOLMSTEDT et al. Levels of metrifonate and dichlorvos in plasma and erythro-cytes during treatment of schistosomiasis with Bilar-cil. Acta Pharmacol Toxicol. (1981) 49(Suppl V) 79–86
   Google Scholar
• BECKER RE, COLLER J, ELBIE R et al.: Effects of metrifo- nate, a long-acting cholinesterase inhibitor, in Alz-heimer's disease: report of an open trial. Drug Dev. Res. (1990) 19:425–434.
   Web of Science ®Google Scholar
• PETTIGREW LC, BIEBER F, LETTIERI J: Pharmacokinet- ics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J. Clin. Pharmacol (1998) 38:236–245.
   PubMed Web of Science ®Google Scholar
• ••A double-blind controlled study in 27 AD patients in whichdifferent doses of metrifonate were given and various phar-macokinetic and pharmacodynamic measures obtained.
   Google Scholar
• CUTLER NR, JHEE SS, CYRUS P et al: Safety and tolerabil-ity of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci. (1998) 62:1433–1441.
   PubMed Web of Science ®Google Scholar
• HOLMSTEDT B, NORDGREN I, SANDOZ M et al: Metrifo-nate: summary of toxicological and pharmacological information available. Arch. Toxicol. (1978) 41:3–29.
   PubMed Web of Science ®Google Scholar
• ••An early paper reviewing a wide range of toxicological data.
   Google Scholar
• LAMB HM, FAULDS D: Metrifonate. Drugs Aging (1997)11:490–496.
   PubMed Web of Science ®Google Scholar
• BECKER RE, COLLIVER JA, MARKWELL SJ et al: Double-blind, placebo-controlled study of metrifonate, an ace-tylcholinesterase inhibitor, for Alzheimer's disease. Alz. Dis. Assoc. Dis. (1996) 10:124–131.
   PubMed Web of Science ®Google Scholar
• BECKER RE, COLLIVER JA, MARKWELL SJ et al.: Effects of metrifonate on cognitive decline in Alzheimer's dis-ease: a double-blind, placebo-controlled 6-month study. Alz. Dis. Assoc. Dis. (1998) 50:1214–1221.
   Google Scholar
• •The earliest efficacy data on relatively long-term use of met-rifonate in humans.
   Google Scholar
• CUMMINGS JL, CYRUS PA, BIEBER F et al.: Metrifonate treatment of the cognitive deficits of Alzheimer's dis-ease. Neurology (1998) 50:1214–1221.
   PubMed Web of Science ®Google Scholar
• ••A large study in which 480 patients were enrolled.
   Google Scholar
• MORRIS JC, CYRUS PA, ORAZEM J et al.: Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease. Neurology (1998) 50:1222–1230.
   PubMed Web of Science ®Google Scholar
• ••One of two large clinical studies of the efficacy ofmetrifonate.
   Google Scholar
• CUMMINGS JL, MEGA M, GRAY K et al.: The neuropsychi- atric inventory: comprehensive assessment of psy-chopathology in dementia. Neurology (1 9 9 4) 44:2308-2314.
   Google Scholar
• CUMMINGS JL, CYRUS PA, RUZICKA BB et al.: The effi-cacy of metrifonate in improving the behavioral dis-turbances of Alzheimer's disease patients. American Academy of Neurology. Minneapolis, USA (1998):S24.004.
   Google Scholar
• GELINAS I, GAUTHIER S, CYRUS PA et al.: The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental ac-tivities of daily living. American Academy of Neurology. Minneapolis, USA (1998):P02.018.
   Google Scholar
• HOLMSTEDT B, NORDGREN I: Toxicological limitations to cholinomimetic therapy. Cholinergic Basis for Alz-heimer Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston (1990:155–161.
   Google Scholar
• KENNEDY SK, LONGNECKER DE: History and Principles of Anesthesiology. In: The Pharmacological Basis of Therapeutics. Goodman Gilman A, Rail TW, Nies AS et al. (Eds.), Pergamon Press, Elmsford, UK (1990269–284.
   Google Scholar
• FLEMING LE, TIMMENY W: Aplastic anemia and pesti- cides: an etiologic association? J. Occup. Med. (1993) 35:1106–1116.
   Google Scholar
• HOAR ZAHM S, BLAIR A: Pesticides and non-hodgkin's lymphoma. Cancer Res. (1992) 52 (Suppl.) :5485S–5488S.
   Google Scholar
• MORIEARTY PL, WOMACK CL, DICK BW et al.: Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man. Am. J. Hematol. (1991) 37:280–282.
   PubMed Web of Science ®Google Scholar
• KARCZMAR A: Anticholinesterases: dramatic aspects of their use and misuse. Neurochem. Int. (1998) 32:401–411.
   PubMed Web of Science ®Google Scholar
• ••A recent review discussing aspects of anticholinesteraseagents other than their use in AD which includes a discus-sion of neuromuscular toxicity.
   Google Scholar